Watch an Expert Opinion video on paroxysmal nocturnal hemoglobinuria with Professor Régis Peffault de Latour

Introduction

Prof. Régis Peffault de Latour (French Reference Center for Aplastic Anemia and PNH, Saint-Louis Hospital, Paris, France) appraises the most important recent and emerging data, and discusses their potential impact on the clinical management of patients living with PNH.

This activity is intended for hematologists and other healthcare professionals involved in the treatment of patients with PNH.

Learning Objectives

After watching this touchEXPERT OPINIONS, you should be able to:

Discuss the current treatment landscape for PNH
Describe the unmet medical needs for PNH with respect to current treatment options
Summarize the evolving treatment landscape and future approaches for the management of PNH

ABOUT PROF. RÉGIS PEFFAULT de LATOUR

Régis Peffault de Latour is based at Saint-Louis Hospital, Paris, where he is Professor of Hematology in the Department of Hematology and Bone Marrow Transplantation.

As a leading clinician with extensive experience encompassing clinical trials and scientific research in the fields of rare immunological and hematological disorders, Prof. Peffault de Latour leads the French Reference Center for Aplastic Anemia and PNH, and is Chair of the French Network for Rare Immunological and Hematological Disorders (MARIH). He also Chairs the EuroBloodNet Bone Marrow Failures (BMF) group, and the European Society for Blood and Bone Marrow Transplantation (EBMT) Severe Aplastic Anaemia Working Party (SAAWP).

Disclosures: Consultancy and honoraria for Alexion Pharmaceuticals, Novartis International AG and Pfizer.

touchCONGRESS: Focus on MET exon 14 skipping alterations – a promising and rapidly evolving molecular target in NSCLC

Touch Neurology

touchEXPERT OPINIONS

Paroxysmal nocturnal hemoglobinuria: from biology to bedside

Introduction

Learning Objectives

Please feed back on these touchEXPERT OPINIONS on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS: Focus on MET exon 14 skipping alterations – a promising and rapidly evolving molecular target in NSCLC

LOGIN or REGISTER to access this content

Introduction

Learning Objectives

Please feed back on these touchEXPERT OPINIONS on the following:(scale 1–5, 1 strongly disagree; 5 strongly agree).

Please feed back on these touchEXPERT OPINIONS on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).